JP2019515648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515648A5 JP2019515648A5 JP2018545380A JP2018545380A JP2019515648A5 JP 2019515648 A5 JP2019515648 A5 JP 2019515648A5 JP 2018545380 A JP2018545380 A JP 2018545380A JP 2018545380 A JP2018545380 A JP 2018545380A JP 2019515648 A5 JP2019515648 A5 JP 2019515648A5
- Authority
- JP
- Japan
- Prior art keywords
- residue
- antibody
- seq
- sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662301271P | 2016-02-29 | 2016-02-29 | |
| US62/301,271 | 2016-02-29 | ||
| PCT/IB2017/000293 WO2017149394A1 (en) | 2016-02-29 | 2017-02-28 | Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515648A JP2019515648A (ja) | 2019-06-13 |
| JP2019515648A5 true JP2019515648A5 (https=) | 2020-04-16 |
| JP7053479B2 JP7053479B2 (ja) | 2022-04-12 |
Family
ID=58530580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545380A Active JP7053479B2 (ja) | 2016-02-29 | 2017-02-28 | ＩＬ７受容体細胞外ドメインα鎖に対する非拮抗性抗体及び癌治療におけるそれらの使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11230602B2 (https=) |
| EP (1) | EP3423496B1 (https=) |
| JP (1) | JP7053479B2 (https=) |
| KR (1) | KR102819051B1 (https=) |
| CN (1) | CN109195987B (https=) |
| AU (1) | AU2017225495B2 (https=) |
| CY (1) | CY1122072T1 (https=) |
| DK (1) | DK3423496T3 (https=) |
| ES (1) | ES2737307T3 (https=) |
| HR (1) | HRP20191445T1 (https=) |
| HU (1) | HUE045183T2 (https=) |
| IL (1) | IL261330B2 (https=) |
| LT (1) | LT3423496T (https=) |
| MA (1) | MA43767B1 (https=) |
| MD (1) | MD3423496T2 (https=) |
| ME (1) | ME03446B (https=) |
| PL (1) | PL3423496T3 (https=) |
| PT (1) | PT3423496T (https=) |
| RS (1) | RS59223B1 (https=) |
| SI (1) | SI3423496T1 (https=) |
| SM (1) | SMT201900460T1 (https=) |
| WO (1) | WO2017149394A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2955196A1 (en) | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| WO2019043065A1 (en) * | 2017-08-29 | 2019-03-07 | Ose Immunotherapeutics | METHOD AND PREPARATION FOR SORTING T EFFECTOR LYMPHOCYTES USING ANTI-CD127 ANTIBODIES FOR CELL THERAPY APPLICATIONS |
| AU2019265888B2 (en) * | 2018-05-10 | 2026-04-09 | Neuracle Science Co., Ltd. | Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof |
| US20220273713A1 (en) * | 2019-06-28 | 2022-09-01 | The University Of Melbourne | Method of inhibiting or activating gamma delta t cells |
| EP4065605A4 (en) | 2019-11-26 | 2023-07-12 | Ramot at Tel-Aviv University Ltd. | Antibodies to carbohydrate antigens |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| WO2021222227A1 (en) * | 2020-04-27 | 2021-11-04 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting cd127 and use thereof |
| AU2021275055A1 (en) * | 2020-05-18 | 2023-02-02 | Mouhannad Jumaa | Composition for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia |
| CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| ES2686593T3 (es) | 2006-05-31 | 2018-10-18 | The Regents Of The University Of California | Expresión de CD127 que correlaciona inversamente con FoxP3 y la función supresora de Treg CD4+ |
| EP1930342B1 (en) | 2006-12-04 | 2012-01-25 | Institut Pasteur | OB-fold used as scaffold for engineering new specific binders |
| GB0724051D0 (en) | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
| UY32038A (es) | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
| WO2010085643A1 (en) | 2009-01-22 | 2010-07-29 | University Of Miami | Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders |
| PE20170687A1 (es) * | 2010-01-28 | 2017-06-13 | Glaxo Group Ltd | Proteinas de enlace a cd127 |
| AR080291A1 (es) | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | Anticuerpos antagonistas anti receptor de il-7 y procedimientos |
| EP2583980A1 (en) | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| US20150297310A1 (en) * | 2014-04-17 | 2015-10-22 | Georgia Regents Research Institute, Inc. | Methods for selecting a treatment for cancer |
| EP2955196A1 (en) | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
-
2017
- 2017-02-28 WO PCT/IB2017/000293 patent/WO2017149394A1/en not_active Ceased
- 2017-02-28 IL IL261330A patent/IL261330B2/en unknown
- 2017-02-28 LT LTEP17716593.3T patent/LT3423496T/lt unknown
- 2017-02-28 ES ES17716593T patent/ES2737307T3/es active Active
- 2017-02-28 AU AU2017225495A patent/AU2017225495B2/en active Active
- 2017-02-28 PL PL17716593T patent/PL3423496T3/pl unknown
- 2017-02-28 DK DK17716593.3T patent/DK3423496T3/da active
- 2017-02-28 SI SI201730078T patent/SI3423496T1/sl unknown
- 2017-02-28 PT PT17716593T patent/PT3423496T/pt unknown
- 2017-02-28 US US16/080,572 patent/US11230602B2/en active Active
- 2017-02-28 HU HUE17716593A patent/HUE045183T2/hu unknown
- 2017-02-28 MA MA43767A patent/MA43767B1/fr unknown
- 2017-02-28 HR HRP20191445 patent/HRP20191445T1/hr unknown
- 2017-02-28 EP EP17716593.3A patent/EP3423496B1/en active Active
- 2017-02-28 MD MDE20190066T patent/MD3423496T2/ro not_active IP Right Cessation
- 2017-02-28 JP JP2018545380A patent/JP7053479B2/ja active Active
- 2017-02-28 ME MEP-2019-215A patent/ME03446B/me unknown
- 2017-02-28 CN CN201780014099.2A patent/CN109195987B/zh active Active
- 2017-02-28 SM SM20190460T patent/SMT201900460T1/it unknown
- 2017-02-28 RS RSP20190987 patent/RS59223B1/sr unknown
- 2017-02-28 KR KR1020187028377A patent/KR102819051B1/ko active Active
-
2019
- 2019-08-23 CY CY20191100905T patent/CY1122072T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515648A5 (https=) | ||
| JP7549621B2 (ja) | Ｏ－アセチル化ＧＤ２ガングリオシド（ＯＡｃＧＤ２）に対するヒト化抗体 | |
| TWI701259B (zh) | ４﹘１ｂｂ抗體及其製備方法和應用 | |
| ES2975063T3 (es) | Anti-CD25 optimizado para FC para el agotamiento celular específico de tumores | |
| JP2026001061A (ja) | 抗ｄｌｌ３キメラ抗原受容体及びその使用 | |
| HRP20191445T1 (hr) | Ne-antagonistička antitijela usmjerena protiv alfa lanca izvanstanične domene il7 receptora i njihova uporaba u liječenju raka | |
| JP2021511818A (ja) | Ｖｉｓｔａ抗原結合性分子 | |
| WO2017127702A1 (en) | Ror2 antibody compositions and related methods | |
| KR20210066865A (ko) | 키메라 항원 수용체 | |
| US20240018248A1 (en) | An ltbr agonist in combination therapy against cancer | |
| JP7584453B2 (ja) | Ｔａｃｉを標的とする抗体及びキメラ抗原受容体 | |
| JP2025063141A (ja) | 抗ｈＫ２キメラ抗原受容体（ＣＡＲ） | |
| US20250026836A1 (en) | Anti-hla-g antibodies | |
| JP2025170264A (ja) | 抗ｂｃｍａ剤のための投与レジメン | |
| WO2022117569A1 (en) | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer | |
| TW202233682A (zh) | 用於投與ＢＣＭＡｘＣＤ３結合分子之方法 | |
| KR102760955B1 (ko) | Gucy2c 결합 폴리펩타이드 및 그의 용도 | |
| JP7813235B2 (ja) | ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法 | |
| KR102290335B1 (ko) | Cd30을 표적으로 하는 키메라 항원 수용체 및 이의 용도 | |
| CN118382455A (zh) | Her2变体car | |
| TWI917473B (zh) | Bcma/taci抗原結合分子 | |
| Li et al. | YMN-V115: a novel humanized BCMA/GPRC5D/CD3 trispecific antibody in relapsed/refractory multiple myeloma | |
| CN117377687A (zh) | 抗癌组合疗法中的ltbr激动剂 | |
| HK40101561A (zh) | 人ccr8结合剂 | |
| HK40103081A (zh) | 鼠交叉反应性人ccr8结合剂 |